2026-01-22 - Analysis Report
## Financial Report for Thermo Fisher (TMO)

### 1. Return Rate Comparison
- Cumulative return of Thermo Fisher (TMO): **45.39%**
- Cumulative return of S&P 500 (VOO): **91.55%**
- Divergence: **-51.90%**
- Relative divergence: **14.30%**

**Analysis**: Thermo Fisher's cumulative return significantly lags behind the S&P 500, indicating underperformance relative to the broader market.

### Company Overview
Thermo Fisher Scientific is a global leader in serving science, providing essential products and services for laboratories and research institutions.

### 2. Recent Stock Price Fluctuations
- Current Close Price: **$636.30**
- Previous Close: **$619.01**
- Change: **$2.79**
- 5-day SMA: **$624.10**
- 20-day SMA: **$603.67**
- 60-day SMA: **$583.82**

**Analysis**: The stock price shows a positive change and is above its moving averages, suggesting a recent upward trend.

### 3. RSI and Market Indicators
- Market Risk Indicator (MRI): **0.80** (Medium Investment)
- RSI: **71.19** (Overbought condition)
- PPO: **0.30**
- Hybrid Signal: **Buy (Cash 0%)**
- Recent relative divergence change (20 days): **0.60 (+)** (improving)
- 7-day Rank change: **31 (+)** (rank up)
- 7-day Dynamic Expected Return change: **-2.90 (-)** (worsening)
- Expected Return: **-43.90%**

**Analysis**: The RSI indicates the stock is overbought, while the MRI suggests medium investment risk. The expected return is negative over the long term compared to the S&P 500.

### 4. Recent News & Significant Events
- **2026-01-21**: P/E Ratio Insights for Thermo Fisher Scientific
- **2026-01-06**: Will Thermo Fisher (TMO) Beat Estimates Again in Its Next Earnings Report?
- **2026-01-06**: Here's How Much You'd Have If You Invested $1000 in Thermo Fisher Scientific a Decade Ago
- **2026-01-21**: Thermo Fisher (TMO) stock rises as Goldman lifts target ahead of Jan. 29 earnings
- **2026-01-15**: Thermo Fisher Scientific Inc. $TMO Stock Position Raised by MGO One Seven LLC
- **2026-01-19**: Thermo Fisher Scientific Inc. (TMO): A Bull Case Theory

**Analysis**: Recent news reflects a mixed sentiment around earnings expectations and stock performance but highlights increased analyst interest.

### 4-2. Analyst Opinions
```text
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.54 (~Buy)
- Opinions: 23
- Target Price (avg/high/low): 652.61 / 750.00 / 575.00
```

### 5. Recent Earnings Analysis
| Date       | EPS  | Revenue   |
|------------|------|-----------|
| 2025-10-31 | 4.28 | 11.12 B$  |
| 2025-08-01 | 4.28 | 10.86 B$  |
| 2025-05-02 | 3.99 | 10.36 B$  |
| 2024-11-01 | 4.26 | 10.60 B$  |
| 2025-10-31 | 4.26 | 10.60 B$  |

**Analysis**: Earnings per share (EPS) have been stable with slight variations, suggesting consistent revenue generation around **$10.36B to $11.12B**.

### 6. Financial Information

#### Revenue and Profitability
| Quarter      | Revenue  | Profit Margin |
|--------------|----------|---------------|
| 2025-09-30   | $11.12B  | 41.21%        |
| 2025-06-30   | $10.85B  | 40.61%        |
| 2025-03-31   | $10.36B  | 40.86%        |
| 2024-12-31   | $11.39B  | 42.32%        |
| 2024-09-30   | $10.60B  | 40.84%        |

#### Capital and Profitability
| Quarter      | Equity   | ROE   |
|--------------|----------|-------|
| 2025-09-30   | $51.02B  | 3.17% |
| 2025-06-30   | $50.51B  | 3.20% |
| 2025-03-31   | $49.39B  | 3.05% |
| 2024-12-31   | $49.59B  | 3.69% |
| 2024-09-30   | $48.99B  | 3.33% |

**Analysis**: Revenue shows consistent growth with stable profit margins around **40-42%**. ROE is low, indicating potential efficiency issues in generating returns from equity.

### 7. Comprehensive Analysis
Thermo Fisher (TMO) has shown a cumulative return of **45.39%** against **91.55%** for the S&P 500, indicating significant underperformance. Recent price movements show a positive trend, yet the stock is at an overbought level with an RSI of **71.19**. EPS figures suggest stable earnings, but the overall outlook remains cautious with an expected return of **-43.90%**. Analyst opinions are moderately positive, suggesting a buying opportunity with a target price average of **$652.61**.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.